Breast cancer affects approximately 1 in 8 women, and it is estimated that over 246,660
women in the USA will be diagnosed with breast cancer in 2016. Breast cancer mortality has …

Drug resistance is a major hurdle in cancer treatment and a key cause of poor prognosis.
Epitranscriptomics and epiproteomics are crucial in cell proliferation, migration, invasion …

Circulating tumour DNA analysis can be used to track tumour burden and analyse cancer
genomes non-invasively but the extent to which it represents metastatic heterogeneity is …

Although it is established that fatty acid (FA) synthesis supports anabolic growth in cancer,
the role of exogenous FA uptake remains elusive. Here we show that, during acquisition of …

The Notch signaling pathway regulates developmental cell-fate decisions and has recently
also been linked to inflammatory diseases. Although therapies targeting Notch signaling in …

Long noncoding RNAs act as crucial regulators in plenty of human cancers, yet their
potential roles and molecular mechanisms in chemoresistance are poorly understood. This …

Abstract HER2/ERBB2–overexpressing breast cancers targeted effectively by the small-
molecule kinase inhibitor lapatinib frequently acquire resistance to this drug. In this study …

Anaplastic large-cell lymphoma (ALCL) is a clinical and biological heterogeneous disease
that includes systemic anaplastic lymphoma kinase (ALK)-positive and ALK-negative …

Purpose: Our goal was to evaluate the safety and toxicity of combining a PARP inhibitor,
olaparib, with cetuximab and fractionated intensity-modulated radiotherapy for patients with …

An estimated 15–20% of breast cancers overexpress human epidermal growth factor
receptor 2 (HER2/ERBB2/neu). Two small-molecule tyrosine kinase inhibitors (TKIs) …